Soligenix, Inc. (SNGX)

Market Cap	8.94M
Revenue (ttm)	2,342
Net Income (ttm)	-9.59M
Shares Out	3.26M
EPS (ttm)	-4.25
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,831,886
Open	2.660
Previous Close	2.930
Day's Range	2.390 - 2.910
52-Week Range	1.090 - 5.400
Beta	1.88
Analysts	Strong Buy
Price Target	6.00 (+118.98%)
Earnings Date	Aug 12, 2025

About BLUE

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. It operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator (IDR) technology that is in Phase 3 clinical trial for the treatment of inflam...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 15, 1987
• Employees: 16
• Stock Exchange: NASDAQ
• Ticker Symbol: SNGX
• Website: https://www.soligenix.com

Financial Performance

In 2024, Soligenix's revenue was $119,371, a decrease of -85.78% compared to the previous year's $839,359. Losses were -$8.27 million, 34.6% more than in 2023.

Financial numbers in CAD

Analyst Summary

According to one analyst, the rating for SNGX stock is "Strong Buy" and the 12-month stock price target is $6.0.

Price Target

$6.0

(118.98% upside)

Analyst Consensus: Strong Buy